home / stock / fprx / fprx quote
$37.75 Last:
-0.03% Change Percent:
$37.8 Open:
$37.75 Previous Close:
$37.93 High:
$37.72 Low:
2,454,327 Volume:
03/08/2021 10:55:23 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2021-03-08 | 37.8 | 37.75 | 37.93 | 37.72 | 2,454,327 |
2021-03-05 | 37.87 | 37.76 | 37.95 | 37.7 | 11,215,074 |
2021-03-04 | 37.99 | 38 | 38.18 | 37.7 | 35,068,075 |
2021-03-03 | 22.31 | 21.26 | 22.44 | 21.13 | 711,228 |
2021-03-02 | 23.06 | 22.31 | 23.4916 | 22.08 | 517,503 |
2021-03-01 | 22.57 | 23.43 | 24.82 | 22.57 | 813,095 |
2021-02-26 | 23.4 | 22.23 | 23.5001 | 21.88 | 690,093 |
2021-02-25 | 25.6812 | 23.08 | 26.25 | 22.86 | 1,473,556 |
2021-02-24 | 23.4 | 25.71 | 25.77 | 22.98 | 1,042,279 |
2021-02-23 | 23.07 | 23.43 | 24.58 | 22.01 | 1,482,080 |
2021-02-22 | 24 | 23.84 | 24.27 | 23.4875 | 1,797,467 |
2021-02-19 | 21.45 | 23.82 | 23.87 | 21.2 | 1,190,495 |
2021-02-18 | 20.43 | 21.44 | 21.92 | 20.2201 | 1,021,257 |
2021-02-17 | 20.23 | 20.83 | 21.14 | 19.63 | 801,836 |
2021-02-16 | 19.51 | 20.08 | 20.2 | 19.03 | 575,195 |
2021-02-15 | 19.93 | 19.51 | 20.465 | 19.5 | 352,120 |
2021-02-12 | 19.93 | 19.51 | 20.465 | 19.5 | 352,098 |
2021-02-11 | 20.39 | 19.92 | 20.46 | 19.4 | 380,959 |
2021-02-10 | 20.35 | 20.14 | 20.87 | 19.62 | 454,269 |
2021-02-09 | 20.81 | 20.39 | 21.4299 | 20.21 | 651,222 |
Five Prime Therapeutics Inc. Company Name:
FPRX Stock Symbol:
NASDAQ Market:
Five Prime Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
On Thursday, Amgen (NASDAQ: AMGN) became the latest big drugmaker to announce an acquisition in 2021. The biotech giant told investors that it will acquire Five Prime Therapeutics (NASDAQ: FPRX) for $1.9 billion in cash. Five Prime Therapeutics is a clinical-stage biotec...
Shares of Five Prime Therapeutics (NASDAQ: FPRX) were skyrocketing 78% higher as of 11:22 a.m. EST on Thursday. The huge jump came after Amgen (NASDAQ: AMGN) announced plans to acquire Five Prime for close to $1.9 billion. Some investors might have sensed that something ...
Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host Investor Call a...